Elliott LaParne focuses on pharmaceutical patent litigation, with an emphasis on Abbreviated New Drug Application (ANDA) litigation.

Elliott applies his extensive research experience to successfully navigate complex pharmaceutical patent cases, combining his scientific background with his formidable litigation skills. As an undergrad, he enhanced his scientific knowledge by conducting Ph.D.-level research on the effects of nicotine on nicotinic acetylcholine receptors in human embryonic stem cells (hESCs) at the University of Pittsburgh School of Medicine. In law school, he authored a regional winning brief in the Saul Lefkowitz Moot Court Competition and demonstrated matching oral advocacy skills that enabled him to place at the national level.